Is IcoSema More Effective Than Insulin Icodec for Type 2 Diabetes?
The phase 3a COMBINE 1 trial finds once-weekly IcoSema lowers HbA1c more than insulin icodec alone while cutting hypoglycemia. PICO summary and expert commentary.
PICO
Structured summariesStructured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
Orforglipron and Cardiovascular Risk Biomarkers in Type 2 Diabetes or Obesity: An Exploratory Phase 2 Analysis
An exploratory analysis of two Phase 2 trials found that oral orforglipron produced placebo-adjusted reductions in cardiovascular risk biomarkers, not clinical events, in adults with type 2 diabetes or obesity. PICO summary and expert commentary.
Does Exenatide Help After Heart Surgery?
A large RCT finds peri-operative exenatide does not reduce death or organ failure after CABG or aortic valve replacement. PICO summary and expert commentary.
Is the Dulaglutide Biosimilar LY05008 Equivalent to Trulicity in Chinese Adults With Type 2 Diabetes?
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 equivalent to reference dulaglutide (Trulicity) for HbA1c reduction at 24 weeks. PICO summary and expert commentary.
Does Tirzepatide Boost Fat Burning Without Changing Metabolism?
A phase 1 mechanistic study in adults with obesity found tirzepatide did not alter metabolic adaptation but increased fat oxidation and reduced calorie intake versus placebo. PICO summary and expert commentary.
Does a GPR119 Agonist Help Glucagon Response in Type 1 Diabetes?
A phase 2a crossover trial finds the GPR119 agonist MBX-2982 does not improve glucagon counterregulation in type 1 diabetes, despite target engagement. PICO summary and commentary.
HEC88473 (Dual GLP-1/FGF21 Agonist): First-in-Human Phase 1 Findings
A phase 1 single-ascending-dose first-in-human trial of HEC88473, a dual GLP-1/FGF21 receptor agonist, reporting tolerability and early metabolic signals in healthy and obese adults. PICO summary and expert commentary.
Does SGLT2 Inhibitor Use Modify Oral Semaglutide’s Cardiovascular Benefit in Type 2 Diabetes?
A prespecified SOUL trial analysis tested whether baseline SGLT2 inhibitor use modified oral semaglutide's cardiovascular benefit in type 2 diabetes. PICO summary and expert commentary.
Once-Weekly Insulin Icodec in Type 2 Diabetes: Consistent Across GLP-1RA and SGLT2i Background Therapy
A post hoc analysis of ONWARDS 1-5 testing whether the efficacy and hypoglycaemia profile of once-weekly insulin icodec versus once-daily basal insulin differs by baseline GLP-1RA or SGLT2i use. PICO summary and expert commentary.